Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

JHOP - February 2022 Vol 12, No 1

Thank You JHOP Peer Reviewers

Case Reports

Dasatinib-Induced Gynecomastia in 2 Patients with Chronic Myeloid Leukemia: Case Reports and Review of the Literature

Jessie Signorelli, PharmD, BCOP; Amir T. Fathi, MD; Gabriela Hobbs, MD

Spontaneous Tumor Lysis Syndrome in a Patient with Stage IV HER2-Positive Breast Cancer: Case Report

Blake T. Robbins, PharmD, MBA; Alexander M. Kreimer, PharmD, BCPS; Reema A. Patel, MD; Allison R. Butts, PharmD, BCOP

Original Article

Evaluation of the Safety and Potential Time-Savings of Subcutaneous Rituximab Administration in a Single Cancer Center

Ashka Patel, PharmD, BCOP; Chirag Patel, MS; Caroline M. Mejías-De Jesús, PharmD, BCOP

Lidocaine plus Tetracaine–Medicated Patch Used for Propofol Sedation During Lumbar Punctures in Pediatric Patients with Blood Cancer

Lisa R. Garavaglia, PharmD; Frank Casey, MD; Lesley Cottrell, PhD; Claudiu Faraon-Pogaceanu, MD; Stephan Paul, MD; Melvin Lee Wright, DO

Review Article

A Review of CAR T-Cell Therapies Approved for the Treatment of Relapsed and Refractory B-Cell Lymphomas

Drew A. Wells, PharmD, BCPS; Jenna Summerlin, PharmD; Zachery Halford, PharmD, BCOP, BCPPS

FDA Oncology Update

Enobosarm Granted Fast-Track FDA Review for AR- and ER-Positive, HER2-Negative Metastatic Breast Cancer

FDA Grants Gedatolisib, a Dual PI3K and mTOR Inhibitor, Fast-Track Review for ER-Positive, HER2-Negative Breast Cancer

Rituximab plus Chemotherapy FDA Approved for Several Pediatric Hematologic Malignancies

Keytruda Now Approved for the Adjuvant Treatment of Stage IIB/IIC Melanoma

Orencia First Drug FDA Approved for the Prevention of Acute Graft-versus-Host Disease

Kimmtrak, a Bispecific CD3 T-Cell Engager, First FDA-Approved Drug for Unresectable or Metastatic Uveal Melanoma

ASH Highlights

Meeting Highlights

Mosunetuzumab, a Bispecific Antibody, Induces Deep Remissions in Relapsed or Refractory Follicular Lymphoma

Meeting Highlights

Time-Limited Venetoclax Combinations Superior to Chemoimmunotherapy in Fit Patients with CLL

Meeting Highlights

Isatuximab plus RVd Regimen Achieves Highest Rates of No MRD in Patients with Multiple Myeloma

Meeting Highlights

Ivosidenib Added to First-Line Azacitidine Improves Outcomes in Older Patients with AML

Meeting Highlights

Polatuzumab Vedotin plus R-CHP Outperforms R-CHOP as First-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma

Meeting Highlights

A Paradigm Shift: CAR T-Cell Therapy Beats Standard of Care as Second-Line Treatment for Large B-Cell Lymphoma

Meeting Highlights

Immune Responses to COVID-19 Vaccines Low Among Patients with Hematologic Malignancies, but mRNA Vaccines Induce Strong Antibody Response in AML and MDS